News NHS funding for five MS drugs under threat NICE calls for further discounts on beta-interferons and Copaxone
News Bayer hit by R&D departure and Xofigo trial The departure of its head of research and the unblinding of a cancer drug trial wrongfooted Bayer late last week, just as the firm wanted to trumpet its broad pipeline.
News US regulator approves new use for Pfizer's Sutent FDA granted new kidney cancer indication despite advisers' split decision
Views & Analysis 7 questions: Bayer's Eugene Borukhovich Eugene Borukhovich's perspective on digital health and its future.
News NICE rejects Bayer and Eisai drugs in thyroid cancer Thyroid cancer drugs are available in Scotland and Wales
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
